Dose range: 150-600 mg daily given in either 2 or 3 divided doses. Neuropathic pain Initially 150 mg daily given as 2 or 3 divided doses. May be increased based on individual patient response & tolerability to 300 mg daily after an interval of 3-7 days if needed. Max: 600 mg daily after an additional 7-day interval. Epilepsy Initially 150 mg daily given as 2 or 3 divided doses. May be increased to 300 mg daily after 1 wk based on individual patient response & tolerability. GAD Initially 150 mg daily. May be increased to 300 mg daily after 1 wk based on individual patient response & tolerability. Max: 600 mg daily after an additional wk.
Diabetic patients w/ wt gain. Discontinue if angioedema eg, facial perioral upper airway swelling occur. Dizziness, somnolence, loss of consciousness, confusion, & mental impairment. Discontinue if loss of vision, visual blurring or changes of visual acuity occurs. W/drawal of concomitant antiepileptic medicinal products. Inform patients prior to starting therapy about the w/drawal symptoms. Patients w/ CHF. Treatment of central neuropathic pain due to spinal cord injury. Monitor for signs of suicidal ideation & behaviors; misuse, abuse potential or dependence. Concomitant use w/ opioid analgesics. Encephalopathy. Galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption. Renal failure. Minor or moderate influence on the ability to drive & use machines. Pregnancy & lactation. Elderly may require dose reduction due to decreased renal function. Childn <12 yr & adolescents.
Sign Out
